Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Bullboard Posts
Post by retiredcopon May 19, 2020 10:30am
259 Views
Post# 31045714

We will know for sure in next few weeks

We will know for sure in next few weeks I strongly believe that we will know very soon if they achieved these remarkable capabilities with the covid serolgy test... I ask myself " why suddenly decide to start putting the effort into the same science for a AD diagnostic and why announce it at this time. Could it be that in the development of this covid test they discovered something very important that they didnt realize  before. Did BCNI validate something that suddenly opens up the ability to produce diagnostics they were reluctant to pursue before
Again my thinking .. everything is mentioned for a specific reason .. sometimes a very subtle hint of an amazing piece of information that the company wants everyone to know about.. 

 
As recently announced, the collaboration between ProMIS and BCNI is making significant progress towards the development of an SPR-based antibody assay, aiming to achieve 100% sensitivity and 99.9% specificity for the virus causing COVID-19. 

 **I was talking with another longtime shareholder about this covid test and I suggested that if a Canadian company can come up  with covid test with all 9's in the specificity .. weshould recognizxer it as the "great one" ..; lets name it the Gretzky Test !  ** 
Bullboard Posts